Leustatin (Cladribine)

Cladribine is taken up by lymphocytes and phosphorylated to its triphosphate form, which becomes incorporated into DNA. This incorporation triggers DNA strand breaks and activates apoptosis pathways, leading to the selective death of malignant B‑cells while sparing most other cell types.

The dosing regimen for Leustatin is determined by the prescribing physician based on the specific indication, patient weight, renal function, and overall clinical status. Physicians follow approved guidelines and adjust the dose as needed; no fixed public dosing schedule is provided.

Safety data for cladribine in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy and breastfeeding unless the potential therapeutic benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is essential.

To order Leustatin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Leustatin (cladribine) belongs to the class of purine nucleoside analogs, similar to fludarabine. Compared with fludarabine, cladribine often requires fewer treatment cycles and may have a different toxicity profile, but both aim to induce lymphocyte apoptosis. Choice of therapy depends on disease characteristics, patient comorbidities, and physician experience.

Leustatin should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the solution. Before administration, inspect the vial for particulate matter and ensure the solution is clear. Follow aseptic technique during preparation and infusion.

Leustatin is given as an intravenous infusion. The solution is diluted according to the prescribing information and infused over a period defined by the treating physician, typically ranging from several minutes to a few hours, under close medical supervision.

The most serious risks include severe infections (including opportunistic infections), profound neutropenia, autoimmune hepatitis, and rare cases of secondary malignancies. Patients should be monitored regularly for signs of infection, liver dysfunction, and blood count abnormalities throughout therapy.

Leustatin is contraindicated in patients with active severe infections, uncontrolled hepatic impairment, or known hypersensitivity to cladribine. Pregnant women should avoid use unless the benefit outweighs the risk. Physicians should also exercise caution in patients with significant renal dysfunction or those receiving other potent immunosuppressants.